Yong‐Zhan Zhen

560 total citations
31 papers, 482 citations indexed

About

Yong‐Zhan Zhen is a scholar working on Molecular Biology, Oncology and Toxicology. According to data from OpenAlex, Yong‐Zhan Zhen has authored 31 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Toxicology. Recurrent topics in Yong‐Zhan Zhen's work include Bioactive Compounds and Antitumor Agents (7 papers), Cancer therapeutics and mechanisms (6 papers) and Phytochemistry and biological activity of medicinal plants (6 papers). Yong‐Zhan Zhen is often cited by papers focused on Bioactive Compounds and Antitumor Agents (7 papers), Cancer therapeutics and mechanisms (6 papers) and Phytochemistry and biological activity of medicinal plants (6 papers). Yong‐Zhan Zhen collaborates with scholars based in China, Türkiye and United States. Yong‐Zhan Zhen's co-authors include Yajun Lin, Jie Wei, Gang Hu, Yong‐Su Zhen, Rong‐Guang Shao, Hongwei He, Gang Hu, Yufang Zhao, Mao‐xu Ge and Shuangshuang Zhao and has published in prestigious journals such as Scientific Reports, British Journal of Pharmacology and Food and Chemical Toxicology.

In The Last Decade

Yong‐Zhan Zhen

31 papers receiving 475 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yong‐Zhan Zhen China 14 212 91 78 63 62 31 482
Yining Lin China 13 358 1.7× 84 0.9× 49 0.6× 79 1.3× 73 1.2× 21 632
Quan Jin China 19 366 1.7× 159 1.7× 64 0.8× 106 1.7× 53 0.9× 33 694
Su‐Yu Chien Taiwan 17 341 1.6× 89 1.0× 63 0.8× 44 0.7× 96 1.5× 21 640
Xianyong Bai China 13 290 1.4× 95 1.0× 157 2.0× 116 1.8× 47 0.8× 20 641
Xinyan Xue China 15 193 0.9× 124 1.4× 108 1.4× 103 1.6× 31 0.5× 28 548
Hui Chai China 15 272 1.3× 127 1.4× 45 0.6× 48 0.8× 49 0.8× 20 547
Jung Yoon Jang South Korea 15 263 1.2× 87 1.0× 57 0.7× 48 0.8× 86 1.4× 22 571
Maysa A. Mobasher Saudi Arabia 12 211 1.0× 79 0.9× 39 0.5× 114 1.8× 46 0.7× 32 514
Yongfang Ding China 12 277 1.3× 80 0.9× 43 0.6× 81 1.3× 28 0.5× 22 506
Shuqiang Yue China 16 465 2.2× 64 0.7× 48 0.6× 56 0.9× 120 1.9× 28 802

Countries citing papers authored by Yong‐Zhan Zhen

Since Specialization
Citations

This map shows the geographic impact of Yong‐Zhan Zhen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yong‐Zhan Zhen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yong‐Zhan Zhen more than expected).

Fields of papers citing papers by Yong‐Zhan Zhen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yong‐Zhan Zhen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yong‐Zhan Zhen. The network helps show where Yong‐Zhan Zhen may publish in the future.

Co-authorship network of co-authors of Yong‐Zhan Zhen

This figure shows the co-authorship network connecting the top 25 collaborators of Yong‐Zhan Zhen. A scholar is included among the top collaborators of Yong‐Zhan Zhen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yong‐Zhan Zhen. Yong‐Zhan Zhen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Yajun, Weiwei Fang, Xin Zhang, et al.. (2022). Tetrandrine Citrate Suppresses Breast Cancer via Depletion of Glutathione Peroxidase 4 and Activation of Nuclear Receptor Coactivator 4-Mediated Ferritinophagy. Frontiers in Pharmacology. 13. 820593–820593. 26 indexed citations
2.
Sun, Jingyu, et al.. (2019). Antitumor activity of tetrandrine citrate in human glioma U87 cells in vitro and in vivo. Oncology Reports. 42(6). 2345–2354. 13 indexed citations
3.
Zhen, Yong‐Zhan, et al.. (2016). Antitumor efficacy of lidamycin against human multiple myeloma RPMI 8226 cells and the xenograft in nonobese diabetic/severe combined immunodeficiency mice. Journal of Cancer Research and Therapeutics. 12(1). 182–182. 3 indexed citations
4.
Xu, Rong, Yajun Lin, Yong‐Zhan Zhen, et al.. (2016). Recombinant adenovirus of human p66Shc inhibits MCF-7 cell proliferation. Scientific Reports. 6(1). 31534–31534. 4 indexed citations
5.
Wei, Jie, Yong‐Zhan Zhen, Ju Cui, et al.. (2016). Rhein lysinate decreases inflammation and adipose infiltration in KK/HlJ diabetic mice with non-alcoholic fatty liver disease. Archives of Pharmacal Research. 39(7). 960–969. 19 indexed citations
6.
Zhen, Yong‐Zhan, et al.. (2015). Effects of rhein lysinate on D-galactose-induced aging mice. Experimental and Therapeutic Medicine. 11(1). 303–308. 35 indexed citations
7.
Zhao, Shuangshuang, Yong‐Zhan Zhen, Mao‐xu Ge, et al.. (2015). Protective effect of gastrodin on bile duct ligation-induced hepatic fibrosis in rats. Food and Chemical Toxicology. 86. 202–207. 32 indexed citations
8.
Liu, Jin, Yong‐Zhan Zhen, Jie Wei, et al.. (2015). Antitumor activity of rhein lysinate against human glioma U87 cells in vitro and in vivo. Oncology Reports. 35(3). 1711–1717. 11 indexed citations
9.
Zhen, Yong‐Zhan, et al.. (2015). Protective effect of bicyclol against bile duct ligation-induced hepatic fibrosis in rats. World Journal of Gastroenterology. 21(23). 7155–7164. 25 indexed citations
10.
Lin, Yajun, et al.. (2014). The protection of Rhein lysinate to liver in diabetic mice induced by high-fat diet and streptozotocin. Archives of Pharmacal Research. 38(5). 885–892. 16 indexed citations
11.
Zhen, Yong‐Zhan. (2013). Lidamycin inhibits mouse myeloma SP2/0 in vivo and in vitro. 1 indexed citations
12.
Lin, Yajun, et al.. (2013). Rhein lysinate inhibits monocyte adhesion to human umbilical vein endothelial cells by blocking p38 signaling pathway. Archives of Pharmacal Research. 36(11). 1410–1418. 5 indexed citations
13.
Hu, Gang, Jiang Liu, Yong‐Zhan Zhen, et al.. (2013). Rhein lysinate increases the median survival time of SAMP10 mice: protective role in the kidney. Acta Pharmacologica Sinica. 34(4). 515–521. 20 indexed citations
14.
Zhen, Yong‐Zhan, Gang Hu, Yufang Zhao, et al.. (2013). Synergy of Taxol and rhein lysinate associated with the downregulation of ERK activation in lung carcinoma cells. Oncology Letters. 6(2). 525–528. 7 indexed citations
15.
Zhen, Yong‐Zhan, et al.. (2013). Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells. Anti-Cancer Drugs. 24(6). 609–616. 2 indexed citations
16.
Lin, Yajun, et al.. (2011). Effects of Rhein Lysinate on H2O2-induced cellular senescence of human umbilical vascular endothelial cells. Acta Pharmacologica Sinica. 32(10). 1246–1252. 31 indexed citations
17.
He, Qihua, Yong‐Zhan Zhen, Shuling Wang, et al.. (2010). Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc. Investigational New Drugs. 29(6). 1188–1197. 9 indexed citations
18.
Zhen, Yong‐Zhan, et al.. (2010). Rhein lysinate inhibits cell growth by modulating various mitogen-activated protein kinases in cervical cancer cells. Oncology Letters. 2(1). 129–133. 12 indexed citations
19.
Zhen, Yong‐Zhan, et al.. (2009). Enediyne lidamycin induces apoptosis in human multiple myeloma cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase. International Journal of Hematology. 90(1). 44–51. 10 indexed citations
20.
Lin, Yajun, Yunhong Huang, Yong‐Zhan Zhen, Xiujun Liu, & Yong‐Su Zhen. (2008). [Rhein lysinate induces apoptosis in breast cancer SK-Br-3 cells by inhibiting HER-2 signal pathway].. PubMed. 43(11). 1099–105. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yining Lin Breakdown of academic impact, for papers by Quan Jin Breakdown of academic impact, for papers by Su‐Yu Chien Breakdown of academic impact, for papers by Xianyong Bai Breakdown of academic impact, for papers by Xinyan Xue Breakdown of academic impact, for papers by Hui Chai Breakdown of academic impact, for papers by Jung Yoon Jang Breakdown of academic impact, for papers by Maysa A. Mobasher Breakdown of academic impact, for papers by Yongfang Ding Breakdown of academic impact, for papers by Shuqiang Yue
Rankless by CCL
2026